Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi And Selecta Target Allergies
by Michael McCoy
December 3, 2012
| A version of this story appeared in
Volume 90, Issue 49
Sanofi and Selecta Biosciences are joining to develop antigen-specific immunotherapies for allergies using Selecta’s synthetic vaccine particle technology. Under the agreement, Sanofi obtains an exclusive license to develop an immunotherapy against a life-threatening food allergen and an option to develop two more allergy therapies. Selecta can receive milestone payments totaling up to $300 million for each of the three drug candidates. Selecta was founded in 2008 by MIT professor Robert Langer and two Harvard Medical School professors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter